[4] The medication causes a reduction in overall levels of IgG, including the abnormal acetylcholine receptor (AChR) antibodies that are present in myasthenia gravis.
[10] Efgartigimod alfa is indicated for the treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive.
[4] More participants receiving efgartigimod alfa also demonstrated response on a measure of muscle weakness compared to placebo.
[4] The trial was conducted at 56 sites in 15 countries in Belgium, Canada, the Czech Republic, Denmark, France, Georgia, Germany, Hungary, Italy, Japan, the Netherlands, Poland, the Russian Federation, Serbia, and the US.
Following a period of 12 weeks, it was observed that 67% of the patients exhibited positive responses to Vyvgart, as evidenced by improvements in their muscle disability scores.
[12] It is also under development for the treatment of primary membranous nephropathy, idiopathic inflammatory myopathy (IIM), anti-neutrophil cytoplasmic antibody-associated vasculitis (ANCA Vasculitis), Graves'' ophthalmopathy, antibody-mediated rejection (AMR), immune-mediated necrotizing myopathy, anti-synthetase syndrome, dermatomyositis, polymyositis, immune thrombocytopenia, primary Sjögren's syndrome, rheumatoid arthritis and pemphigus.
The amount of circulating IgG decreases and therefore prevents the acetylcholine receptors from being degraded by the autoantibodies that are responsible for the myasthenia gravis.